Skip to main content
SpringerLink
Log in

Prognosis and epidemiology of plasmocytomas

  • Chapter
Gammopathy

  • 52 Accesses

Abstract

The introduction of the alkylating agents was a milestone in the therapy and prolongation of the post-diagnosis survival of the patients with plasmocytoma. The survival rate has been expanded from 6–12 months (32, 57) to 30–36 months (29). Numerous other monoand polychemotherapy protocols failed to statistically significantly further prolong the survival rate (3, 9). The promising exceptionally beneficial results of some schemes could not, however, be adequately controlled. The analysis of the beneficial results and fiascos made the specialists first to look for a single (?) factor responsible for the prolongation of the survival rate and then to determine those clinical and laboratory tests, which can be applied for the evaluation of the tumour mass.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alexanian, R., Balberzak, S., Bonnet, J. D., Geham, E. A. Haut, A., Hewlett, J. S., Monto, R. W. Prognostic factors in multiple myeloma. Cancer. 36, 1192. 1975.

    Article  PubMed  CAS  Google Scholar 

  2. Alexanian, R. Localised and indolent myeloma. Blood. 56, 521. 1980.

    PubMed  CAS  Google Scholar 

  3. Alexanian, R., Dreicer, R. Chemotherapy for multiple myeloma. Cancer. 55, 583. 1984.

    Article  Google Scholar 

  4. Alexanian, R. Treatment of multiple myeloma. Acta Haematol. 63, 237. 1980.

    Article  PubMed  CAS  Google Scholar 

  5. Barlogie, B., Latrielle, J., Alexanian, R., Swartzengruber, D. E.,Smallwood, L., Maddox, A. M., Raker, M. N., Drewinko, B. Quantitative cytology in myeloma research. Clin. Haematol. 11, 19. 1982.

    PubMed  CAS  Google Scholar 

  6. Bartl, R., Frisch, B., Burkhardt, R. Multiple myeloma. Bone Marrow Biopsies Revisited. Karger. Basel. 42. 1982.

    Google Scholar 

  7. Bartl, R., Frisch, B., Burkhardt, R., Fateh- Moghadam, A., Mahl, G., Gierster, P., Sund, M., Kettner, G. Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging. Brit. J. Haematol. 51, 361. 1982.

    Article  CAS  Google Scholar 

  8. Bataille, R., Durie, B. G. M., Grenier, J. Serum béta-2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Brit. J. Haematol. 55, 439. 1983.

    Article  CAS  Google Scholar 

  9. Bergsagel, D. E. Progress in the treatment of plasma cell myeloma. J. Clin. Oncol. 1,510. 1983.

    PubMed  CAS  Google Scholar 

  10. Bergsagel, D. E. Prognostic factors in plasma cell myeloma. Eur. J. Canc. Clin. Oncol. 19, 1493. 1983.

    CAS  Google Scholar 

  11. Bettini, R., Steidl, L., Rapazzani, P., Giardina, G. Prognostic value of the staging system proposed by Merlini, Waldenström and Jayakar for multiple myeloma. Acta Haematol. 70, 378. 1983.

    Article  Google Scholar 

  12. Blattner, W. A. Epidemiology of multiple myeloma and related plasma cell disorders: an analytic review. In: Progress in myeloma. Ed: by Potter, M. Elsevier North-Holland. N. Y. 1, 1980.

    Google Scholar 

  13. Boccadoro, M., Gavarotti, P., Fossati, L. Pileri, A., Marmont, F., Nerotto, G., Gallamino, A., Volta, C, Tribalto, M., Testa, M. G., Amadori, S., Mandelli, F., Durie, B.G.M. Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a relable indicator of patients not requiring therapy. Brit. J. Haematol. 58, 689. 1984.

    Article  CAS  Google Scholar 

  14. Boga, Marianna, Jákó, J., Domán, J., Magyar, Éva, Konyár, E. Familial myeloma. Folia Haematol. 3, 201. 1973.

    Google Scholar 

  15. Bourguet, C. Claire, Grufferman, S., Delzell, Elizabeth, DeLong, R. Elizabeth, Cohen, H. J. Multiple myeloma and family history of cancer. Cancer. 56, 2133. 1985.

    Article  PubMed  CAS  Google Scholar 

  16. Buckman, R., Guzick, J., Galton, D. A. G. Long term survival in myelomatosis. Brit. J. Haematol. 52, 589. 1982.

    Article  CAS  Google Scholar 

  17. Bunn, P. A., Krasnow, S., Makuch, R. W., Selam, M. L., Schechter, G. P. Flow cytometric analysis of DNA content of bone marrow cells in patients with plasma cell myeloma: clinical implications. Blood. 59, 528. 1982.

    PubMed  Google Scholar 

  18. Burmeister, L. F., Burmeister G. D., Van Lier, S. F., Isacson, P. Selected cancer mortality and farm practices in Iowa. Amer. J. Epidemiol. 118, 72. 1983.

    CAS  Google Scholar 

  19. Cavo, V., Baccarani, M., Gobbi, A. Lipizer, A., Tura, S. Prognostic value of bone marrow plasma cell infiltration in stage I multiple myeloma. Brit. J. Haematol. 55, 683. 1983.

    Article  CAS  Google Scholar 

  20. Cuzick, J. Radiation-induced myelomatosis. N. Engl. J. Med. 304, 204. 1981.

    Article  PubMed  CAS  Google Scholar 

  21. Cuzick, J., Velez, R., Doll, R. International variations and temporal trends in mortality from multiple myeloma. Internat. J. Cancer. 32, 13. 1983.

    Article  CAS  Google Scholar 

  22. Decoufle, P., Stanislawczyk, K., Houten, L. A retrospective survey of cancer in relation to occupation. DHEW (NIOSH) Publication. 77, 1977.

    Google Scholar 

  23. Dorken, H., Vollmer, I. The epidemiology of multiple myeloma — investigation of 149 cases. Arch. Geschwulstforsch. 31, 18. 1968.

    PubMed  CAS  Google Scholar 

  24. Drewinko, B., Alexanian, R., Boyer, H. The growth fraction of human myeloma cells. Blood. 57, 333. 1981.

    PubMed  CAS  Google Scholar 

  25. Durie, B. G. M., Salmon, S. E. A clinical staging system for multiple myeloma. Cancer. 36, 842. 1975.

    Article  PubMed  CAS  Google Scholar 

  26. Durie, B. G. M., Salmon, S. E., Moon, T. E. Pretreatment tumour mass, cell kinetics and prognosis in multiple myeloma. Blood. 55, 364. 1980.

    PubMed  CAS  Google Scholar 

  27. Durie, B. G. M., Salmon, S. E., Murdy, G. R. Relation of osteoclast growth: interrelationships between drug sensitivity, cell kinetics and activating factor production to extent of bone disease in multiple patient survival duration. Blood. 61,929. 1981.

    Google Scholar 

  28. Durie, B. G. M. Staging and kinetics of multiple myeloma. Clinics in Haematol. 11,3. 1982.

    CAS  Google Scholar 

  29. Durie, B. G. M., Salmon, S. E. The current status and future prospects of treatment for multiple myeloma. Clinics in Haematol. 11, 181. 1982.

    CAS  Google Scholar 

  30. Durie, B. G. M., Young, L. A., Salmon, S. E. Human myeloma in vitro colony myeloma.Brit. J. Haematol. 47, 21. 1983.

    Article  Google Scholar 

  31. Endo, T., Okumura, H., Kikuchi, K., Munakata, J., Otake, M., Nomura, T., Asakawa, H. Immunoglobulin E (IgE) multiple myeloma. A case report and review of the literature. Amer. J. Med. 70, 1127. 1981.

    Article  PubMed  CAS  Google Scholar 

  32. Feinleib, M., MacMahon, B. Duration of survival in multiple myeloma. J. Nat. Cancer Inst. 24, 1259. 1960.

    PubMed  CAS  Google Scholar 

  33. Fritz, E., Ludwig, H., Kundi, M. Prognostic relevance of cellular morphology in multiple myeloma. Blood. 63, 1072. 1984.

    PubMed  CAS  Google Scholar 

  34. Gassmann, W., Pralle, H., Haferlach, T., Pandurevič, S., Graubner, M., Schmitz, N., Loffler, H. Staging system for multiple myeloma: a comparison. Brit. J. Haematol. 59, 703. 1968.

    Article  Google Scholar 

  35. Grepp, P. R., Raymond, N. M., Kyle, R. A., O’Fallon, W. M. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood. 63, 305. 1985.

    Google Scholar 

  36. Gramont, A., Benitez, O., Smadja, N., Brissand, P., Sirenelli, A., Hubert, D., Krulik, M., Debray, J. Bone marrow plasma cell infiltration in multiple myeloma. Brit. J. Haematol. 57, 351. 1984.

    Google Scholar 

  37. Hamburger, A. W., Salmon, S. E. Primary bioassay of human myeloma stem cells. J. Clin. Invest. 60, 846. 1977.

    Article  PubMed  CAS  Google Scholar 

  38. Hobbs, J. R. Growth rates and response to treatment in human myelomatosis. Brit. J. Haematol. 16, 607. 1969.

    Article  CAS  Google Scholar 

  39. Hoffman, V., Salmon, S. E., Durie, B. G. M. Drug resistance in multiple myeloma associated with high in vitro incorporation of 3(H) thymidine. Blood. 58,471. 1981.

    Google Scholar 

  40. Ichimaru, M., Ishimaru, T., Mikami, M. Multiple myeloma among atomic bomb survivors in Hiroshima and Nagasaki by dose 1950–1976. Radiation Effects Research Report, Technical Report. 9. 1979.

    Google Scholar 

  41. Isomaki, H. A., Hakulinen, T.;Joutsenlahti, U. Excess risk of lymphoma, leukaemia and myeloma in patients with rheumatoid arthritis. J. Chronic. Dis. 31,691. 1978.

    Article  PubMed  CAS  Google Scholar 

  42. Jancelwiez, Z., Talatsuki, K., Sugai, S., Pruzanski, W. IgD multiple myeloma. Arch. Intern. Med. 135, 87. 1975.

    Article  Google Scholar 

  43. Jákó, J., Virágh, Sz., Schopper, J., Sebők, J., Juhász, J. Nierenerkrankungen bei monoclonalen Gammopathien — eineklinisch-pathologische Studie. Immun. Infekt. 9,60. 1981.

    PubMed  Google Scholar 

  44. Kyle, R. A. Multiple myeloma: a review of 869 cases. Mayo Clinic Proc. 50, 29. 1975.

    CAS  Google Scholar 

  45. Kyle, R. A.,Grepp, P. R. Smouldering multiple myeloma. N. Engl. J. Med. 302, 1374. 1980.

    Google Scholar 

  46. Kyle, R. A. Long term survival in multiple myeloma. N. Engl. J. Med. 308, 314. 1983.

    Article  PubMed  CAS  Google Scholar 

  47. Lee, B. J., Myers, J. Long term survival in myeloma. N. Engl. J. Med. 308, 243. 1983.

    Google Scholar 

  48. Liang, W., Hopper, J. E., Rowley, J. D. Karyotypic abnormalities and clinical aspects of patients with multiple myeloma and related paraproteinaemic diseases. Cancer. 44, 630. 1979.

    Article  PubMed  CAS  Google Scholar 

  49. Matzner, Y., Benbassat, J., Polliack, A. Prognostic factors in multiple myeloma. Acta Haematol. 60, 257. 1978.

    Article  PubMed  CAS  Google Scholar 

  50. Merlini, G., Waldenström, J. G., Jayakar, S. D. A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. Blood. 55, 1011, 1980.

    PubMed  CAS  Google Scholar 

  51. Milham,S. Leukemia and multiple myeloma in farmers. Amer. J. Epidemiol. 94, 307. 1971.

    Google Scholar 

  52. Milham, S. Occupational mortality in Washington State, 1950–1971. DHEW (NIOSH) Publication 76, 1976.

    Google Scholar 

  53. MRC Working Party on Leukaemia in Adults. Report on the first myelomatosis trial. part 1. Analysis of presenting features of prognostic importance. Brit. J. Haematol. 24, 123. 1973.

    Article  Google Scholar 

  54. MRC Working Party of Leukaemia in Adults. Prognostic features in the third myelomatosis trial. Brit. J.Cancer. 42, 831. 1980.

    Article  Google Scholar 

  55. Nathans, D., Fahey, J. L., Potter, M. The formation of myeloma protein by a mouse plasma cell tumour. J. Exp. Med. 108, 121. 1958.

    Article  PubMed  CAS  Google Scholar 

  56. Norfolk, D., Child, J. A., Cooper, E. H., Kerruish, S., Milford Ward, A. Serum beta-2 microglobulin in myelomatosis; potential value in stratification and monitoring. Brit. J. Cancer. 42,510. 1980.

    Article  PubMed  CAS  Google Scholar 

  57. Osgood, E. E. The survival time of patients with plasmacytic myeloma. Cancer Chemotherapy Reports. 9, 1. 1960.

    CAS  Google Scholar 

  58. Osmond, C, Gardner, M. J. Age, period and cohort models applied to cancer mortality rates. Statistical Medicine. 1, 245. 1982.

    Article  CAS  Google Scholar 

  59. Otieno, L. S., Ogada, T. Multiple myeloma at Kenyatta National Hospital, 1973–1976. East African Med. J. 54, 574. 1977.

    CAS  Google Scholar 

  60. Salmon, S. E., Smith, B. A. Immunoglobulin synthesis and total body tumour cell number in IgG multiple myeloma. J. Clin. Invest. 49, 1114. 1970.

    Article  PubMed  CAS  Google Scholar 

  61. Salmon, S. E., Hamburger, A. W., Soehnlen, B. J., Durie, B. G. M., Alberts, D. S., Moon, T. E. Quantitation of differential sensitivity of human tumour stem cells to anticancer drugs. N. Engl. J. Med. 298, 1321. 1978.

    Article  PubMed  CAS  Google Scholar 

  62. Salmon, S. E. Cloning and chemosensitivity of myeloma stem cells. Clin. Haematol. 11, 47. 1982.

    PubMed  CAS  Google Scholar 

  63. Scarffe, H., Anderson, H., Palmer, M. K., Crowther, D. Prognostic significance of pretreatment serum beta-2 microglobulin levels in multiple myeloma. Eur. J. Cancer Clin. Oncol. 19, 1361. 1983.

    Article  PubMed  CAS  Google Scholar 

  64. Schur, P. H., Kyle, R. A., Block, K. J., Hammack, W. J., Rivers, S. L., Sargent, A., Ritchie, R. F., McIntyre, O. R., Moloney, W. C, Wolfson, L. IgG subclasses: relationship to clinical aspects of multiple myeloma and frequency distribution among M-components. Scand. J. Haematol. 12, 60. 1974.

    Article  PubMed  CAS  Google Scholar 

  65. Skipper, H. E. Thoughts on cancer chemotherapy and combination modality therapy. J. Amer. Med. Ass. 230, 1033. 1974.

    Article  CAS  Google Scholar 

  66. Sullivan, P. W., Salmon, S. E. Kinetics of tumours growth and regression in IgG multiple myeloma. J.Clin. Invest. 51,1697. 1972

    Article  PubMed  CAS  Google Scholar 

  67. Velez, R., Beral, V., Cuzick, J. Increasing trends of multiple myeloma mortality in England and Wales; 1950–79; are the changes real? J. Nat. Cancer Inst. 69, 387. 1982.

    PubMed  CAS  Google Scholar 

  68. Waldbaum, B., Gelfand, M. Myelomatosis in the Rhodesian African. Tropical Geographical Med. 26, 26. 1974.

    CAS  Google Scholar 

  69. Waterhouse, J. Muir, C, Shanmugaratnam, K., Powell, J. Cancer incidence in five continents, vol IV. IARC publication No 42. Lyon. 1982.

    Google Scholar 

  70. Woodruff, R. K., Wodsworth, J., Malpass, J. S., Tobias, J. S. Clinical staging of multiple myeloma. Brit. 7. Haematol. 42. 199. 1979.

    Article  CAS  Google Scholar 

  71. Wurster-Hill, D. H., Mclntyre, O. R., Cornwell, G. G. Chromosome studies in myeloma. Virch. Arch. ’B Cell Path. 29, 93. 1978.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 1st Department of Medicine, Postgraduate Medical School, Szabolcs u. 35, 1135, Budapest, Hungary

    Professor János Jákó

Authors
  1. Professor János Jákó
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Jákó János, Budapest

About this chapter

Cite this chapter

Jákó, J. (1991). Prognosis and epidemiology of plasmocytomas. In: Gammopathy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84929-9_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-84929-9_9

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-84931-2

  • Online ISBN: 978-3-642-84929-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation